Research Ethics Committee Reference Number	Integrated Research Applicatio n System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/NE/0399	215044	A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)	Number Agreed	1	1	Date Agreed	28/02/2018	1	30/11/2017	1	Recruitment Finished
16/SC/0435	212314	An Open-label Long-term Extension Safety Study of Intranasal Esketamine inTreatment-resistant Depression Safety and Sustenance of Esketamine Treatment Response With Repeated Doses at Intervals Determined by Symptom Severity (SUSTAIN-3)	Number Agreed	2	2	Date Agreed	31/03/2018	2	12/10/2017	2	Recruitment Finished
17/YH/0196	228435	A Phase 2 Randomized, Investigator-Blind, Placebo- Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia	Number Agreed	15	15	Date Agreed	30/09/2019	1	06/04/2018	1	Withdrawn By Sponsor